NCT06723405View on ClinicalTrials.gov

Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 13, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Atopic Dermatitis (AD)EczemaEczema Atopic Dermatitis
Interventions
BIOLOGICAL

EVO301

Intravenous EVO301

BIOLOGICAL

Placebo

Placebo

Trial Locations (12)

1010

Optimal Clinical Trials, Auckland

2120

Momentum Clinical Research Pukekohe, Pukekohe

3204

Clinical Trials New Zealand Ltd, Hamilton

5010

Momentum Clinical Research Lower Hutt, Hutt Central

5032

Momentum Clinical Research Kapiti, Paraparaumu

7011

Pacific Clinical Research Network (PCRN) Tasman, Nelson

8013

Pacific Clinical Research Network (PCRN) Christchurch, Christchurch

9016

Momentum Clinical Research Dunedin, Dunedin

QLD 4151

Cornerstone Dermatology, Coorparoo

NSW 2010

Momentum Clinical Research Darlinghurst, Darlinghurst

0622

Pacific Clinical Research Network (PCRN) Auckland, Auckland

0632

Optimal Clinical Trials North, Auckland

Sponsors

Lead Sponsor

Evommune, Inc.
All Listed Sponsors
lead

Evommune, Inc.

INDUSTRY

NCT06723405 - Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter